3 Things Pfizer's Coronavirus Vaccine Still Has to Prove
The U.S. Food and Drug Administration met with its vaccines advisory panel of experts on Dec. 10 to discuss Pfizer's (NYSE: PFE) coronavirus vaccine candidate. The FDA agreed with the panel and granted Pfizer and partner BioNTech (NASDAQ: BNTX) Emergency Use Authorization for the product. But the two months of follow-up data on trial participants reported so far isn't enough to answer all questions about the vaccine. In this Motley Fool Live video recorded on Dec. 11, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com contributor Adria Cimino discuss key elements Pfizer's vaccine must address in the coming months.
Source Fool.com
